Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!
Composition of medication for treating high blood pressure
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A composition and high blood pressure technology, applied in the direction of drug combination, pharmaceutical formula, cardiovascular system diseases, etc., can solve problems such as poor prognosis, many complications, and low cure rate
Inactive Publication Date: 2011-09-14
苏金平
View PDF1 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
However, there are the following problems: first, the main pathogenic factors of most diseases are unknown; second, most diseases have more complications; third, even if the etiology is known, it is almost impossible for a chemical component to inhibit all causes
However, as hypertension is a disease with uncertain etiology, the cure rate of drugs targeting one or more effects of one etiology or mechanism of action is relatively low. Usually, the cure rate of one drug is about 40-50%, and poor prognosis
In recent years, although there are many new antihypertensive drugs with good curative effect and few side effects, the blood pressure control rate can only reach 50-60%
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
[0054] It is worth mentioning that the dosage of calcium is based on Ca 2+ It is added in proportion to the calcium-containing component.
[0055] (M ca 2+ / M HF *100%)
[0056] Indicates the amount of calcium;
[0057] W HF Indicates the amount of calcium-containing components in the formula;
[0058] Indicates the percentage of calcium in the calcium-containing component.
[0059] The beneficial effects of the composition of the present invention in the preparation of medicines for treating hypertension will be further illustrated below through animal experiments and human observations. attached Figures 1 to 5 Based on the experimental results of the furosemide+calcium group; attached Figures 6 to 10 Based on the experimental effect of hydrochlorothiazide + calcium group.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
A composite medicine for treating hypertension contains diuretic, a Ca-contained component and accessory which is acceptable in pharmacy, wherein the weight ratio between the diuretic and the Ca-contained component is in the range of 1:10-2000. The diuretic is chosen from furosemidum, ethacrynic acid, bumetanide, torasemide, hydrochlorothiazinde, chlorothiazide, hygroton, metolazone, quinethazone, triamterene, amiloride, spirolactone or acetazolamide, the Ca-contained component is chosen from shell, keel, inorganic Ca salt, organic Ca salt, etc, wherein the shell comprises concha margaritiferallsta, oyster, concha haliotidis or activative product calcium oxide; inorganic Ca salt and organic Ca salt comprise calcium chloride, Ca carbonate, Ca phosphate, Ca citrate, Ca lactate, Ca gluconate or Ca L-threonate .The composite medicine is capable of decreasing blood pressure by rapidly reducing blood volume, wherein the Ca-contained component can restrain the level of booster factors in body to enhance depressurization effects of the diuretic.
Description
technical field [0001] The present invention relates to a pharmaceutical composition, more specifically, the present invention relates to a pharmaceutical composition for treating hypertension. Background technique [0002] Hypertension is one of the most common cardiovascular diseases at present. It is mainly manifested clinically by increased systemic arterial pressure, often accompanied by various complications such as stroke, myocardial infarction, heart failure, coronary heart disease, and diabetes. Europe and North America are high incidence areas of hypertension. Surveys show that the prevalence of hypertension among adults in my country is 18.8%. It is estimated that the number of patients nationwide is 160 million, an increase of more than 70 million compared with 1991. The prevalence of hypertension in rural areas is rising rapidly, and the gap between urban and rural areas is not obvious. Generally speaking, the life expectancy of hypertensive patients is 15-20 y...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.